Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

• Status: Completed
• Trial end date: 2021-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate whether the use of Sugammadex for reversing the neuromuscular blocking effects of rocuronium during neurointerventional procedures can speed recovery of neuromuscular function. Half of participates will receive Neostigmine with glycopyrrolate, while the other half will receive Sugammadex.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Treatments: Glycopyrrolate; Neostigmine

Criteria

Inclusion Criteria:

• Age ≥ 18 years;

• American Society of Anesthesiologists (ASA) physical status 1-3;

• Scheduled for catheter-based neurointerventional procedures including coiling and stent insertion;

• General anesthesia.

Exclusion Criteria:

• Suspected difficult intubation;

• Neuromuscular disorder;

• Renal impairment creatinine ≥ 2 mg /dl;

• Hepatic dysfunction;

• History of malignant hyperthermia;

• Allergy to neuromuscular blocking drugs, Sugammadex, neostigmine or glycopyrrolate;

• Perioperative respiratory infections and/or pneumonia;

• Intubated or unresponsive;

• Pregnancy or breastfeeding.